Get the Stockscreener App
17.77
0.28%
-0.05
Zai Lab Limited Adr stock is traded at $17.77, with a volume of 851.96K.
It is down -0.28% in the last 24 hours and down -18.78% over the past month.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
See More
Previous Close:
$17.82
Open:
$18.28
24h Volume:
851.96K
Relative Volume:
1.06
Market Cap:
$1.97B
Revenue:
$418.33M
Net Income/Loss:
$-252.07M
P/E Ratio:
-7.4042
EPS:
-2.4
Net Cash Flow:
$-238.84M
1W Performance:
-8.87%
1M Performance:
-18.78%
6M Performance:
-58.70%
1Y Performance:
-33.50%
1-Day Range:
$17.72
$18.67
1-Week Range:
$17.72
$19.50
52-Week Range:
$17.72
$44.34
Zai Lab Limited Adr Stock (ZLAB) Company Profile
Name
Zai Lab Limited Adr
Sector
Industry
Phone
862161632588
Address
899 HALEI ROAD, SHANGHAI
Compare ZLAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZLAB
Zai Lab Limited Adr
|
17.77 | 1.97B | 418.33M | -252.07M | -238.84M | -2.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Zai Lab Limited Adr Stock (ZLAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-25-25 | Resumed | Jefferies | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Mar-03-25 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-14-23 | Initiated | Morgan Stanley | Overweight |
| Aug-10-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-21-22 | Initiated | Macquarie | Outperform |
| Oct-12-21 | Initiated | Bernstein | Mkt Perform |
| Apr-28-20 | Initiated | Goldman | Buy |
| Apr-15-20 | Initiated | Guggenheim | Buy |
| Jul-12-19 | Initiated | BofA/Merrill | Buy |
| Jul-05-19 | Initiated | Macquarie | Outperform |
| Jan-29-19 | Initiated | Credit Suisse | Outperform |
| Nov-21-18 | Initiated | Jefferies | Buy |
| Jun-21-18 | Resumed | Leerink Partners | Outperform |
| Feb-14-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Initiated | JP Morgan | Neutral |
| Oct-16-17 | Initiated | Leerink Partners | Outperform |
View All
Zai Lab Limited Adr Stock (ZLAB) Latest News
How Investors Are Reacting To Zai Lab (ZLAB) Advancing ZL-1503 And Securing Key NRDL Renewals - Sahm
Zai Lab (NASDAQ:ZLAB) Hits New 1-Year LowShould You Sell? - MarketBeat
Zai Lab Announces Updates to China’s National Reimbursement Drug List - Business Wire
Zai Lab Limited (ZLAB) Moves 21.5% Higher: Will This Strength Last? - MSN
What Zai Lab (ZLAB)'s Q3 Results and Reaffirmed 2025 Guidance Mean for Shareholders - Sahm
Zai Lab (ZLAB) Remains a Buy Amid Strong Commercial and Pipeline Momentum - Finviz
Mitchells & Butlers (LON:MAB) Shares Up 7.2% – Should You Buy? - Defense World
Analysts Set Aardvark Therapeutics, Inc. (NASDAQ:AARD) PT at $30.63 - Defense World
Hamilton Insurance Group, Ltd. (NYSE:HG) Receives $28.63 Average Target Price from Brokerages - Defense World
Brokerages Set Circle Internet Group, Inc. (NYSE:CRCL) Price Target at $150.33 - Defense World
Analyzing YY Group (NASDAQ:YYGH) and Cintas (NASDAQ:CTAS) - Defense World
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Zai Lab (NASDAQ:ZLAB) Sees Strong Trading VolumeHere's Why - MarketBeat
Boston Partners Sells 690,421 Shares of Synchrony Financial $SYF - Defense World
Boston Partners Purchases 1,111 Shares of Wells Fargo & Company $WFC - Defense World
CocaCola Company (The) $KO Shares Purchased by Boston Partners - Defense World
Boston Partners Reduces Position in The Travelers Companies, Inc. $TRV - Defense World
Boston Partners Buys 525,214 Shares of Trimble Inc. $TRMB - Defense World
Zai Lab Ltd. Sponsored ADR (ZLAB) Stock Price Today | Live Chart & News - Traders Union
Can Zai Lab Limited (1ZLB) stock test all time highsQuarterly Portfolio Review & High Conviction Buy Zone Alerts - newser.com
EBITDA per share of Zai Lab Ltd. Sponsored ADR – SWB:1ZL - TradingView
UBS Lists CN Stocks w/ Highest Potential FY26 Earnings Upside (Table) - AASTOCKS.com
Zai Lab Limited (NASDAQ:ZLAB) Analysts Are Cutting Their Estimates: Here's What You Need To Know - simplywall.st
Analyst Forecasts Just Became More Bearish On Zai Lab Limited (NASDAQ:ZLAB) - simplywall.st
There is no doubt that Zai Lab Limited ADR (ZLAB) ticks all the boxes. - Setenews
Check Out Companhia Siderurgica Nacional ADR (SID)’s Trade Data Rather Than the Analysts’ Views - Setenews
symbol__ Stock Quote Price and Forecast - CNN
Stocks of Super Group (SGHC) Limited (SGHC) are poised to climb above their peers - setenews.com
Zai Lab (NASDAQ:ZLAB) Sets New 1-Year Low After Earnings Miss - Defense World
Zai Lab Ltd (ZLAB) Q3 2025 Earnings: EPS Loss of $0.03 Beats Est - GuruFocus
Revenues Working Against Zai Lab Limited's (NASDAQ:ZLAB) Share Price Following 26% Dive - simplywall.st
Zai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate Updates - Business Wire
Why Zai Lab Limited (1ZLB) stock appeals to dividend investors2025 Bull vs Bear & Real-Time Buy Zone Alerts - Fundação Cultural do Pará
Brokerages Set Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Price Target at $56.35 - Defense World
Keeping an Eye on Nine Energy Service Inc (NINE) After Insider Trading Activity - knoxdaily.com
Zai Lab (NasdaqGM:ZLAB): Evaluating Valuation Following Promising Trial Results and Phase 3 Progress - Sahm
EBITDA per share of Zai Lab Ltd. Sponsored ADR – GETTEX:1ZL - TradingView
Did Zai Lab’s (ZLAB) Promising Zoci Trial Results Just Shift Its Investment Narrative? - Sahm
Zai Lab (ZLAB) to Release Quarterly Earnings on Thursday - MarketBeat
Zai Lab Announces Participation in Investor Conferences in November and December 2025 - The Globe and Mail
Zai Lab Announces Participation in Investor Conferences in September 2025 - Markets Financial Content
Zai Lab (NASDAQ:ZLAB) Stock Price Down 4.6%Time to Sell? - MarketBeat
Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study - Business Wire
Q3 Earnings Estimate for Zai Lab Issued By Leerink Partnrs - MarketBeat
Zai Lab Secures RMB300 Million Debt Facility - The Globe and Mail
[8-K] Zai Lab Ltd Reports Material Event | ZLAB SEC FilingForm 8-K - Stock Titan
Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025 - The Globe and Mail
Zai Lab (NASDAQ:ZLAB) Trading Down 6.2%Here's What Happened - MarketBeat
Late‑breaking Phase 1 data for Zoci: Zai Lab to present DLL3‑targeted ADC results at AACR Oct 24, 2025 - Stock Titan
Operating cash flow per share of Zai Lab Ltd. Sponsored ADR – BER:1ZL - TradingView
Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference - Business Wire
Zai Lab Limited Adr Stock (ZLAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):